138139-14-7

Basic information

• Product Name: (3-BROMOPHENOXY) ACETIC ACID ETHYL ESTER
• Synonyms: (3-BROMOPHENOXY) ACETIC ACID ETHYL ESTER;Ethyl (3-bromophenoxy)acetate
• CAS NO: 138139-14-7
• Molecular Formula: C₁₀H₁₁BrO₃
• Molecular Weight: 259.1
• Mol File: 138139-14-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Room temperature.
• CAS DataBase Reference: (3-BROMOPHENOXY) ACETIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (3-BROMOPHENOXY) ACETIC ACID ETHYL ESTER(138139-14-7)
• EPA Substance Registry System: (3-BROMOPHENOXY) ACETIC ACID ETHYL ESTER(138139-14-7)

Safety Data

• Hazardous Substances Data: 138139-14-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(3-Bromophenoxy) acetic acid ethyl ester is used as a key intermediate in the synthesis of various organic compounds, particularly in the preparation of pharmaceutical and agrochemical products. Its unique structure and reactivity make it a valuable component in the development of novel drug molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (3-Bromophenoxy) acetic acid ethyl ester is used as a starting material for the synthesis of various drug candidates. Its potential biological activities and therapeutic applications have been studied, contributing to the discovery of new medications with improved efficacy and safety profiles.
Used in Agrochemical Industry:
(3-Bromophenoxy) acetic acid ethyl ester is also utilized in the agrochemical industry for the development of new pesticides and other crop protection agents. Its unique chemical properties allow for the creation of innovative agrochemical products with enhanced performance and reduced environmental impact.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (3-Bromophenoxy) acetic acid ethyl ester is employed as a research tool to explore its potential biological activities and therapeutic applications. Its study contributes to the understanding of molecular mechanisms and the development of new treatment strategies for various diseases and conditions.

Upstream product

• 591-20-8 3-Bromophenol 
• 105-39-5 chloroacetic acid ethyl ester 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 1798-99-8 3-bromophenoxyacetic acid 
• 496052-50-7 1-bromo-3-(fluoromethoxy)benzene 
• 1181678-29-4 [(2'-methoxybiphenyl-3-yl)oxy]acetic acid 
• 308292-49-1 C₈H₉BrN₂O₂ 
• 1263183-71-6 C₁₃H₁₀BrN₃O₂S 
• 299443-53-1 C₉H₈BrN₃OS 
• 1263183-96-5 C₉H₁₀BrN₃O₂S 

Relevant articles and documents

DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE

Provided herein are a dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B. Specifically, provided herein is a compound having Formula (I) or (Ia), or a stereisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.

Dihydropyridine compound and application thereof to drugs

The invention relates to a dihydropyridine compound and application of the dihydropyridine compound serving as a drug, in particular to application of the dihydropyridine compound serving as a drug for treating and preventing hepatitis B. Specifically, the invention relates to the compound shown as the general formula (I) or (Ia) (please see the specifications for the general formula (I) or (Ia))or stereoisomers, tautomer, a nitrogen oxide, solvate, metabolites and medically acceptable salt of the compound or a prodrug of the compound, wherein all variables are defined in the specification. The invention further relates to application of the compound shown as the general formula (I) or (Ia) or enantiomers, non-enantiomers, the tautomer, hydrates, the solvate or the medically acceptable salt of the compound serving as drugs, in particular to application of the compound or the enantiomers, the non-enantiomers, the tautomer, the hydrates, the solvate or the medically acceptable salt of the compound serving as the drugs for treating and preventing hepatitis B.

Synthesis toward Bivalent Ligands for the Dopamine D2 and Metabotropic Glutamate 5 Receptors

In this study, we designed and synthesized heterobivalent ligands targeting heteromers consisting of the metabotropic glutamate 5 receptor (mGluR5) and the dopamine D2 receptor (D2R). Bivalent ligand 22a with a linker consisting of 2

Radical decarboxylative fluorination of aryloxyacetic acids using N-fluorobenzenesulfonimide and a photosensitizer

Fluorinated methoxy arenes are emerging as important motifs in both agrochemicals and pharmaceuticals. A novel technique for the synthesis of monofluoromethoxy arenes through the direct fluorodecarboxylation of carboxylic acids was developed that uses photosensitizers and N-fluorobenzenesulfonimide (NFSI). Utilization of the oxidatively mild fluorine transfer agent NFSI enabled the synthesis of fluoromethyl ethers that were previously inaccessible with decarboxylative fluorinations performed with Selectfluor. Mechanistic studies are consistent with the photosensitizer effecting oxidation of the aryloxyacetic acid.

Photo-fluorodecarboxylation of 2-aryloxy and 2-aryl carboxylic acids

Coming to light: The title reaction simply requires an aqueous alkaline solution of Selectfluor and light. The method is inexpensive and effective for a wide range of neutral and electron-poor 2-aryloxy and 2-aryl acetic acids to provide fluoromethyl ethers (see scheme) and benzyl fluorides, respectively. The mechanism most likely proceeds through an initial aryl excitation with a subsequent single-electron transfer. Copyright

Synthesis and xanthine oxidase inhibitory activity of 7-methyl-2- (phenoxymethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one derivatives

An elevated level of blood uric acid (hyperuricemia) is the underlying cause of gout. Xanthine oxidase is the key enzyme that catalyzes the oxidation of hypoxanthine to xanthine and then to uric acid. Allopurinol, a widely used xanthine oxidase inhibitor is the most commonly used drug to treat gout. However, a small but significant portion of the population suffers from adverse effects of allopurinol that includes gastrointestinal upset, skin rashes and hypersensitivity reactions. Moreover, an elevated level of uric acid is considered as an independent risk factor for cardiovascular diseases. Therefore use of allopurinol-like drugs with minimum side effects is the ideal drug of choice against gout. In this study, we report the synthesis of a series of pyrimidin-5-one analogues as effective and a new class of xanthine oxidase inhibitors. All the synthesized pyrimidin-5-one analogues are characterized by spectroscopic techniques and elemental analysis. Four (6a, 6b, 6d and 6f) out of 20 synthesized molecules in this class showed good inhibition against three different sources of xanthine oxidase, which were more potent than allopurinol based on their respective IC50 values. Molecular modeling and docking studies revealed that the molecule 6a has very good interactions with the Molybdenum-Oxygen-Sulfur (MOS) complex a key component in xanthine oxidase. These results highlight the identification of a new class of xanthine oxidase inhibitors that have potential to be more efficacious, than allopurinol, to treat gout and possibly against cardiovascular diseases.

Glycomimetic selectin inhibitors: (α-D-mannopyranosyloxy)methylbiphenyls

A novel class of biphenyl-based compounds were investigated for their ability to inhibit sialyl Lewis X (sLe(X) dependent binding of HL-60 cells to E- and P-selectin fusion proteins. Compounds (2b) and (2h) demonstrated improved binding as compared to both the natural ligand sLe(X) and a previously reported inhibitor TBC-265 (1, R = 3-CH2CO2H).

Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa

This invention relates to compounds that inhibit the binding of E-selectin and/or P-selectin to sialyl-Lewisx or sialyl-Lewisa presented on a cell surface having the general structure STR1 wherein X is selected from the group consisting of --(CH2)n CO2 H, --O(CH2)m CO2 H, --(CH2)n O(CH2)m CO2 H, --CONH(CH2)m CO2 H, --CH(OZ)(CO2 H), --CH(Z)(CO2 H), --(CH2)n SO3 H, --(CH2)n PO3 D1 D2, --NH(CH2)m CO2 H, --CONH(CHR6)CO2 H, (1-H-tetrazolyl-5-alkyl-), and --OH; R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, halogen, --OZ, --NO2, --NH2 and --NHZ; R3 is selected from the group consisting of hydrogen, halogen, alkyl, --OZ and --NHZ; R4 is selected from the group consisting of hydrogen, halogen, alkyl, hydroxyl, hydroxyl-O-sulfate and --OZ; R5 is selected from the group consisting of hydroxyl, --CN, --N3, --NH2, --NHNH2, --NE1 E2, --NHE1, --NHCO(CH2)n CO2 H, --S(CH2)m CO2 H and --NHCHNHNH2 ; R6 is selected from the group consisting of hydrogen, alkyl, aralkyl, hydroxyalkyl, aminoalkyl, alkyl carboxylic acid and alkyl carboxamide; wherein n is 0 to 6, m is 1 to 6, p is 0 to 6, b is 0 to 2, Z is alkyl, aryl or aralkyl, D1 and D2 are independantly hydrogen or alkyl, E1 is alkyl or --(CH2)8 CO2 H, and E2 is alkyl, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. This invention also relates to methods of inhibiting the binding of E-selectin and/or P-selectin to sialyl-Lewisx or sialyl-Lewisa presented on a cell surface using said compounds and to pharmaceutically active compositions comprising compounds that inhibit the binding of E-selectin to sialyl-Lewisx and to methods of treatment of septic shock, ARDS, Crohn's disease, chronic inflammatory diseases, such as psoriasis and rheumatoid arthritis, and reperfusion injuries that occur following heart attacks, strokes and organ transplants.

16-Phenoxy and 16-substituted phenoxy-prostatrienoic acid derivatives

Novel racemic and 8R-antimeric 16-phenoxy- and 16-(o, m or p)-substituted phenoxy derivatives of 9α, 11α,15-trihydroxy-17,18,19,20-tetranorprosta-4,5,13-trans-trienoic acids, which may be further substituted at C-15 by a methyl or ethyl group, the pharmaceutically acceptable, non-toxic lower alkyl esters and salts thereof and processes for the production of such compounds. dl 9α,11α,15α-trihydroxy-16-m-trifluoromethylphenoxy-17,18,19,20-tetranorprosta-4,5,13-trans-trienoic acid and dl 9α,11α,15 -trihydroxy-15 -methyl-16-m-trifluoromethylphenoxy-17,18,19,20-tetranorprosta-4,5,13-trans-trienoic acid are representative compounds of the class. These compounds possess prostaglandin-like activities and thus are useful in the treatment of mammals where prostaglandins are indicated. They are particularly useful as luteolytic agents in female mammals.